David J. Woodhouse - Nov 18, 2021 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC (NGM)

Role
Chief Executive Officer, Director
Signature
/s/ Valerie Pierce, Attorney-in-fact
Stock symbol
NGM
Transactions as of
Nov 18, 2021
Transactions value $
-$187,200
Form type
4
Date filed
11/19/2021, 06:39 PM
Previous filing
Aug 16, 2021
Next filing
Dec 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NGM Common Stock Options Exercise $113K +15K $7.54 15K Nov 18, 2021 Direct
transaction NGM Common Stock Sale -$300K -15K -100% $20.02* 0 Nov 18, 2021 Direct F1, F2
holding NGM Common Stock 80K Nov 18, 2021 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Options Exercise $0 -15K -5.56% $0.00 255K Nov 18, 2021 Common Stock 15K $7.54 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 18, 2021.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.07. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Shares held by The Woodhouse Family Trust 9/8/05.
F4 Fully vested.